Medication Guide App

Meropenem Pregnancy and Breastfeeding Warnings

Meropenem is also known as: Merrem, Merrem Novaplus

Meropenem Pregnancy Warnings

AU: This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus. UK: Use should be avoided. US: This drug should be used during pregnancy only if clearly needed. AU TGA pregnancy category: B2 US FDA pregnancy category: B

Animal studies have failed to reveal evidence of fetal harm, although slight changes in fetal body weight were noted. There are no controlled data in human pregnancy. AU TGA pregnancy category B2: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals are inadequate or may be lacking, but available data show no evidence of an increased occurrence of fetal damage. US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

Meropenem Breastfeeding Warnings

A mother was treated with 1 g IV every 8 hours for 7 days while her newborn was exclusively breastfed. Five samples of hindmilk were collected and the average breast milk level was 480 mcg/L. Estimated average and maximum infant intake were 71 mcg/kg/day (0.13% of weight-adjusted maternal dose) and 97 mcg/kg/day (0.18% of weight-adjusted maternal dose), respectively. When asked later, the mother stated her infant had no symptoms of oral thrush, watery diarrhea, or diaper dermatitis requiring antifungal therapy during therapy or during the month after therapy.

AU: Use is not recommended unless the benefit outweighs the risk to the infant. UK: A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. US: Caution is recommended. Excreted into human milk: Yes Comments: -This drug is not expected to cause harmful effects in the nursing infant. -Clinical monitoring of infants for altered gastrointestinal flora has been suggested; loose bowel movement may occur in the nursing infant. -This drug is considered compatible with breastfeeding according to the Therapeutic Guidelines Antibiotic Edition, version 14.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web2)